Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

NCT04427072 PHASE3 TERMINATED Results posted

The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small cell lung cancer (NSCLC) with certain specific genetic alterations (called mutations) of a gene called MET, within a specific part of the gene called exon 14.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE3
Status	TERMINATED
Enrolment	22
Start date	Fri Sep 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Nov 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• Capmatinib
• Docetaxel

Countries

France, Italy, Netherlands, Russia, South Africa, Malaysia, Belgium, Germany, Hungary, South Korea, Vietnam, Lithuania, Bulgaria, Thailand, Portugal, Spain, Brazil, India